Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Pearce IP BioBlast™: w/e 24 July 2020

by | Jul 27, 2020

Significant biosimilar activities this week include

20 Jul 20 | EU | Spherix reported that the EU market for AbbVie’s Humira® has been negatively impacted by gastroenterologists increasingly prescribing alternative mechanism of action agents, including Stelara® (ustekinumab) and Entyvio® (vedolizumab) for ulcerative colitis (UC) and Crohn’s disease (CD) and the increased prescription of adalimumab biosimilars.  These increases have come at a cost to AbbVie, with use of Humira® in UC and CD decreasing in the EU.

21 Jul 20 | Novartis released its Q2 FY20 financial results, reporting COVID-19 negatively impacted demand for Lucentis® (ranibizumab).

22 Jul 20 | IN | Cadila Pharma announced it has launched Bevaro® (biosimilar bevacizumab) in India.  Bevaro® is indicated for ovarian cancer, glioblastoma, colorectal cancer, breast cancer, lung cancer, cervical cancer and kidney cancer.

22 Jul 20 | Biogen released its Q2 FY20 financial results, reporting a 7% decrease in biosimilar revenues compared to FY19.

22 Jul 20 | Genentech published the results from its Ph III Archway study,  evaluating its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD).  Genentech reported that 98.4% of patients were able to go six months without requiring additional treatment, and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections.

23 Jul 20 | EU | The CHMP adopted a positive opinion recommending the granting of marketing authorisation for Centus Biotherapeutics’ Equidacent® (biosimilar bevacizumab) for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.

23 Jul 20 | Roche released its Q2 FY20 results, reporting 1% growth, but a 4% decline when adjusted to Swiss francs.  The decline was attributed to COVID-19 impacts, biosimilar competition and a stronger Swiss franc.  In particular, biosimilars for Herceptin® (trastuzumab), Avastin® (bevacizumab) and MabThera/Rituxan® (rituximab) impacted upon sales in the US and Japan.

24 Jul 20 | A new study published by the Journal of Clinical Pathways demonstrates significant cost-savings generated by Sandoz’s pegfilgrastim biosimilar Ziextenzo®.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News